An Oral Pill in a Diabetes Population

ATTAIN-2 tested orforglipron — a daily tablet with no food or water restrictions — for weight in 1,613 adults who had both obesity and type 2 diabetes. The top dose reached −9.6% at 72 weeks against −2.5% on placebo.^[1] The number most readers will want next is how that compares to the injections, and this page is going to explain why we are not going to give it to you.

What the trial did

Across 136 sites in ten countries, people whose BMI was at least 27 and whose HbA1c sat between 7% and 10% took a once-daily tablet at one of three strengths — 6, 12 or 36 mg — or a matching placebo, alongside lifestyle modification, for 72 weeks. The allocation ran 1:1:1:2 — a deliberately doubled placebo arm, which is why 630 people took placebo against roughly 330 in each active group. Nine in ten of the 1,613 enrolled saw the trial through, 1,444 in all.

Participants started at an average weight of 101.4 kg, a BMI of 35.6, and an HbA1c of 8.05%. What the trial set out to measure was the percentage of starting weight lost, analyzed on the treatment-regimen estimand — meaning everyone randomized is counted regardless of whether they stopped the drug, which is the more conservative of the two ways to report a weight trial.

Every dose separated from placebo at p<0.0001, and the dose-response is orderly — each step up produced more weight loss, which is what you want to see and is not always what appears. Every prespecified weight and cardiometabolic measure, HbA1c included, improved significantly.

Why we will not put this beside SURMOUNT-1

The obvious rejoinder is that there is a fairer comparator — the tirzepatide trial that also enrolled people with diabetes. That is a better instinct, and it is still a cross-trial comparison. Different investigators, different sites, different eligibility rules, different placebo responses, different years. The gap between two trials’ placebo arms alone can be larger than the difference anyone is trying to detect.

What we can say without inventing a comparison: type 2 diabetes reliably lowers weight loss on every drug in this class, in every trial that has looked. That pattern is robust across the literature, which means a reader with diabetes should calibrate against trials run in people with diabetes — whatever the drug. Our tirzepatide timeline and semaglutide timeline each report their own trials on their own terms for exactly this reason.

The comparison you want requires a trial that has not been run. Saying so is more useful than a number that looks like an answer. ★ There is a formal method that gets closer than reading across headlines — anchoring two trials through their placebo arms — and we take apart what it can and cannot settle in comparing trials that never met.

Safety, and one sentence we cannot resolve

Discontinuations for adverse events ran from 6.1% to 9.9% across the orforglipron doses against 4.1% on placebo, driven mainly by gut effects. Those were rarely severe, and they bunched into the weeks when the dose was climbing — the same shape the injectables show, and the reason a titration schedule exists at all.

Ten deaths occurred: six on orforglipron, four on placebo. Here the published abstract says something we cannot fully reconcile. It reports that investigators deemed all deaths unrelated to study treatment except one case in the placebo group and one in the 12 mg orforglipron group — and then, in the next sentence, that for the orforglipron case no treatment-related association was reported.

In absolute terms, ten deaths across 1,613 people over 72 weeks — six on drug against four on a placebo arm half the size — is a small number in a population with obesity and type 2 diabetes, and a trial this size is not designed to detect a mortality difference in either direction.

What it is useful for

• It is double-blind and placebo-controlled, which the pill-versus-pill head-to-head is not — see the first pill-versus-pill trial for why that matters with these particular drugs.
• It reports the conservative estimand. The treatment-regimen figure counts people who stopped; the efficacy estimand, which flatters every weight trial, was supportive only.
• The dose-response is clean, which is evidence the effect is the drug rather than the trial.
• It says nothing about cardiovascular or kidney outcomes, where semaglutide has an evidence base no oral non-peptide yet approaches.

For what orforglipron is and how it is labeled, see Foundayo.